Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy

Bibliography

• TERNANSKY RJ, DRAHEIM SE, PIKE AJ et al.: Discovery and structure–activity relationship of a series of 1-carba-1-dethiacephems exhibiting activity against methicillin-resistant Staphylococcus aureus. J. Med. Chem. (1993) 36:1971-1976.
   PubMed Web of Science ®Google Scholar
• HAMMOND GG, OVERBYE KM, SILVER LL: Binding of L-695,256, a prototypical 2-aryl carbapenem antibiotic, to penicillin binding proteins of methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus hirae. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, USA (4 – 7 October 1994).
   Google Scholar
• CHAMBERLAND S, BLAIS J, BOND S, MATHIAS KM, LEE VJ: In vitro antibacterial activity and bioprofiling of MC02,306 and analogs against resistant Gram-positive organisms. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA (17 – 20 September 1995).
   Google Scholar
• HARTMAN BJ, TOMASZ A: Low-affinity penicillin-binding protein associated with β-lactam resistance in Staphylococcus aureus. J. Bacteriol. (1984) 158:513-516.
   PubMed Web of Science ®Google Scholar
• NOEL GJ, STRAUSS RS, PYPSTRA R, GROUP TS: Successful treatment of complicated skin infections (cSSSI) due to staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA) with ceftobiprole. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA (17 – 20 September 2006).
   Google Scholar
• HEBEISEN P, HEINZE-KRAUSS I, ANGEHRN P et al.: In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. (2001) 45:825-836.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA T, MATSUNAGA N, TAWADA H et al.: TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg. Med. Chem. (2003) 11:2427-2437.
   PubMed Web of Science ®Google Scholar
• ENTENZA JM, HOHL P, HEINZE-KRAUSS I, GLAUSER MP, MOREILLON P: BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. (2002) 46:171-177.
   PubMed Web of Science ®Google Scholar
• BOGDANOVICH T, EDNIE LM, SHAPIRO S, APPELBAUM PC: Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. (2005) 49:4210-4219.
   PubMed Web of Science ®Google Scholar
• BOZDOGAN B, ESEL D, WHITENER C, BROWNE FA, APPELBAUM PC: Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. (2003) 52:864-868.
   PubMed Web of Science ®Google Scholar
• DESHPANDE L, RHOMBERG PR, FRITSCHE TR, SADER HS, JONES RN: Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn. Microbiol. Infect. Dis. (2004) 50:73-75.
   PubMed Web of Science ®Google Scholar
• DESHPANDE LM, JONES RN: Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect.. (2003) 9:1120-1124.
   PubMed Web of Science ®Google Scholar
• JONES RN, DESHPANDE LM, MUTNICK AH, BIEDENBACH DJ: In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. (2002) 50:915-932.
   PubMed Web of Science ®Google Scholar
• VON EIFF C, FRIEDRICH AW, BECKER K, PETERS G: Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob. Agents Chemother. (2005) 49:4372-4374.
   PubMed Web of Science ®Google Scholar
• DENIS O, DEPLANO A, NONHOFF C et al.: In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob. Agents Chemother. (2006) 50:2680-2685.
   PubMed Web of Science ®Google Scholar
• DAVIES TA, SHANG W, BUSH K: Activities of ceftobiprole and other β-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob. Agents Chemother. (2006) 50(7):2530-2532.
   PubMed Web of Science ®Google Scholar
• KOSOWSKA K, HOELLMAN DB, LIN G et al.: Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. (2005) 49:1932-1942.
   PubMed Web of Science ®Google Scholar
• ARIAS CA, SINGH KV, MURRAY BE: Evaluation of ceftobiprole in a mouse model of peritonitis due to Enterococcus faecalis including a β-lactamase-positive strain. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA (17 – 20 September 2006).
   Google Scholar
• BROWN NP, JONES ME, DRAGHI DC et al.: Baseline surveillance profiles of ceftobiprole (BPR) activity against Enterobacteriaceae and Pseudomonas aeruginosa (PA). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA (17 – 20 September 2006).
   Google Scholar
• FRITSCHE TR, SADER HS, JONES RN: In vitro activity of ceftobiprole tested against a recent collection of North American Pseudomonas aeruginosa. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA (17 – 20 September 2006).
   Google Scholar
• AMSLER K, BUSH K, WIRA E, FOLENO B: In vitro susceptibility of ceftobiprole against non-fermenting clinical isolates. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (16 – 19 December 2005).
   Google Scholar
• KRESKEN M, HAFNER D, HAFNER D, SEIFERT H ON BEHALF OF THE WORKING GROUP ANTIMICROBIAL RESISTANCE OF THE PAUL EHRLICH SOCIETY FOR CHEMOTHERAPY: Susceptibilities of most prevalent Enterobacteriaceae-species to ceftobiprole: results of the Antimicrobial Resistance Surveillance Study of the Paul Ehrlich Society for Chemotherapy, 2004. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA (17 – 20 September 2006).
   Google Scholar
• EDNIE LM, SHAPIRO S, APPELBAUM PC: Anti-anaerobic activity of ceftobiprole compared to other agents. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA (17 – 20 September 2006).
   Google Scholar
• GOLDSTEIN EJ, CITRON DM, MERRIAM CV et al.: In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob. Agents Chemother. (2006) 50:3959-3962.
   PubMed Web of Science ®Google Scholar
• WOOTTON M, BOWKER KE, HOLT HA, MACGOWAN AP: BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. J. Antimicrob. Chemother. (2002) 49:535-539.
   PubMed Web of Science ®Google Scholar
• CHAMBERS HF: Ceftobiprole: in vivo profile of a bactericidal cephalosporin. Clin. Microbiol. Infect. (2006) 12(Suppl. 2):17-22.
   PubMed Web of Science ®Google Scholar
• ANDES DR, CRAIG WA: In vivo pharmacodynamics of RO 63-9141 (BAL9141) against multiple bacterial pathogens. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (17 – 20 September 2000).
   Google Scholar
• AZOULAY-DUPUIS E, BEDOS JP, MOHLER J et al.: Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother. (2004) 48:1105-1111.
   PubMed Web of Science ®Google Scholar
• ROUSE MS, HEIN MM, ANGUITA-ALONSO P, STECKELBERG JM, PATEL R: Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn. Microbiol. Infect. Dis. (2006) 55:333-336.
   PubMed Web of Science ®Google Scholar
• VAUDAUX P, GJINOVCI A, BENTO M et al.: Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2005) 49:3789-3793.
   PubMed Web of Science ®Google Scholar
• CHAMBERS HF: Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. (2005) 49:884-888.
   PubMed Web of Science ®Google Scholar
• SCHMITT-HOFFMANN A, HARSCH H, HEEP M et al.: BAL5788 in patients with complicated skin and skin structure infections caused by Gram-positive pathogens including methicillin-resistant Staphylococcus species (MRSA). Pharmacokinetic results from 27 patients. 14th European Congress on Clinical Microbiology and Infectious Disease, Prague, Czech Republic (1 – 4 May 2004).
   Google Scholar
• SCHMITT-HOFFMANN A, MURTHY B, STRAUSS RS, PYPSTRA R: Pharmacokinetics (PK) of multiple infusions of ceftobiprole (1000 mg every 8 hours) in healthy volunteers. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA (17 – 20 September 2006).
   Google Scholar
• SCHMITT-HOFFMANN A, NYMAN L, ROOS B et al.: Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. (2004) 48:2576-2580.
   PubMed Web of Science ®Google Scholar
• SCHMITT-HOFFMANN A, ROOS B, HEEP M, AL E: Influence of gender on the pharmacokinetics of BAL9141 after intravenous infusion of pro-drug BAL5788. 14th European Congress on Clinical Microbiology and Infectious Disease, Prague, Czech Republic (1 – 4 May 2004).
   Google Scholar
• SCHMITT-HOFFMANN A, ROOS B, SCHLEIMER M et al.: Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. (2004) 48:2570-2575.
   PubMed Web of Science ®Google Scholar
• SCHMITT-HOFFMANN AH, ROOS B, SCHLEIMER M, AL E: Dose adjustment in subjects with normal and impaired renal function based on the pharmacokinetics of BAL5788. 14th European Congress on Clinical Microbiology and Infectious Disease, Prague, Czech Republic (1 – 4 May 2004).
   Google Scholar
• LODISE TP, DRUSANO GL, MA L et al.: Pharmacodynamic profiling of ceftobiprole for the treatment of complicated skin and skin structure infections and nosocomial pneumonia. 16th European Congress on Clinical Microbiology and Infectious Disease, Nice, France (1 – 4 April 2006).
   Google Scholar
• MOUTON JW, SCHMITT-HOFFMANN A, SHAPIRO S, NASHED N, PUNT NC: Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob. Agents Chemother. (2004) 48:1713-1718.
   PubMed Web of Science ®Google Scholar
• HEEP M, QUERNER S, HARSCH M, O'RIORDAN W: Ceftobiprole (BAL5788), the first of a new class of anti-MRSA cephalosporins-microbiological results from a Phase II study in complicated skin and skin structure infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (30 October – 2 November 2004).
   Google Scholar
• UEDA Y, KANAZAWA K, EGUCHI K et al.: In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Antimicrob. Agents Chemother. (2005) 49:4185-4196.
   PubMed Web of Science ®Google Scholar
• UEDA Y, ITOH M, SASAKI A, SUNAGAWA M: SM-216601, a novel parenteral 1β-methylcarbapenem: structure-activity relationships of antibacterial activity and neurotoxicity in mice. J. Antibiot. (Tokyo) (2005) 58:118-140.
   PubMed Web of Science ®Google Scholar
• TAKAYAMA Y, YOSHIDA T, HIRAE Y et al.: ME1036, a novel parenteral carbapenem: in vitro and in vivo bactericidal activities of ME1036 against methicillin-resistant Staphylococcus aureus. Chemotherapy, San Francisco, USA (17 – 20 September 2006).
   Google Scholar
• KOGA T, ABE T, INOUE H et al.: In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob. Agents Chemother. (2005) 49:3239-3250.
   PubMed Web of Science ®Google Scholar
• THOMSON KS, MOLAND ES: CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. J. Antimicrob. Chemother. (2004) 54:557-562.
   PubMed Web of Science ®Google Scholar
• KAWAMOTO I, SHIMOJI Y, KANNO O et al.: Synthesis and structure–activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. J. Antibiot. (Tokyo) (2003) 56:565-579.
   PubMed Web of Science ®Google Scholar
• SHIBAYAMA T, MATSUSHITA Y, HIROTA T, IKEDA T, KUWAHARA S: Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers. Antimicrob. Agents Chemother. (2006) 50:4186-4188.
   PubMed Web of Science ®Google Scholar
• IIZAWA Y, NAGAI J, ISHIKAWA T et al.: In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J. Infect. Chemother. (2004) 10:146-156.
   PubMed Web of Science ®Google Scholar
• SADER HS, FRITSCHE TR, KANIGA K, GE Y, JONES RN: Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob. Agents Chemother. (2005) 49:3501-3512.
   PubMed Web of Science ®Google Scholar
• JONES RN, FRITSCHE TR, GE Y, KANIGA K, SADER HS: Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J. Antimicrob. Chemother. (2005) 56:1047-1052.
   PubMed Web of Science ®Google Scholar
• ANDES D, CRAIG WA: Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. (2006) 50:1376-1383.
   PubMed Web of Science ®Google Scholar
• GE Y, FLOREN L, REDMAN R, WIKLER M, LIAO S: Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA (17 – 20 September 2006).
   Google Scholar
• GE Y, FLOREN L, REDMAN R, WIKLER M, LIAO S: The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA (17 – 20 September 2006).
   Google Scholar
• THYE D, GE Y, DAS A, TALBOT GH: Randomized, observer-blinded, Phase II study of the efficacy and safety of ceftaroline vs. vancomycin and aztreonam in complicated skin and skin structure infections (cSSSI). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA (17 – 20 September 2006).
   Google Scholar
• BRADFORD PA, WEAVER-SANDS DT, PETERSEN PJ: In vitro activity of tigecycline against isolates from patients enrolled in Phase III clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. (2005) 41(Suppl. 5):S315-S332.
   PubMed Web of Science ®Google Scholar
• KUTI JL, NIGHTINGALE CH, NICOLAU DP: Pharmacodynamics of RO4908463 (CS-023), a novel carbapenem, against Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PSA). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (30 October – 2 November 2004).
   Google Scholar